Transcutaneous Auricular Vagus Nerve Stimulation in Perimenopause

November 16, 2026 updated by: Anna Carolyna Lepesteur Gianlorenco, Spaulding Rehabilitation Hospital

Transcutaneous Auricular Vagus Nerve Stimulation in Perimenopause: EEG Signatures of Symptom Modulation

The study will test an ear-based nerve stimulation (taVNS) to see if it can ease common perimenopause symptoms like hot flashes, poor sleep, mood changes, and "brain fog". Along the way, brain activity (EEG) and heart rhythm patterns (HRV) will be tracked to find simple, reliable signs of improvement.

Because women with both mild and more severe symptoms early in the transition are included, the results can learn who benefits most and why. If successful, this study will set the stage for larger trials and could make taVNS a low-risk, affordable option to support women's brain and overall health during perimenopause.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

56

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion criteria:

  • Perimenopausal women aged 35-60 with climacteric symptoms for >6 months, irregular menstruation, and at least one menses in the past 6 months.
  • Women on menopausal hormone therapy (HRT).
  • Ability to understand procedures and provide informed consent.
  • Willingness to complete study visits, questionnaires, EEG/HRV recordings, taVNS sessions.
  • Negative urine pregnancy test.
  • Access to stable internet for remote sessions or willingness to use study-provided equipment.

Exclusion criteria:

  • Pregnancy, breastfeeding, or planning pregnancy during the active study period (for randomized subjects).
  • Postmenopausal status.
  • History of implanted stimulator.
  • Clinically significant unstable cardiac disease.
  • History of seizure disorder or serious neurological condition that interferes with study procedures or EEG interpretation.
  • Current ear infection.
  • Active severe psychiatric instability.
  • Recent initiation or major dose change of hormone therapy, psychotropics, beta-blockers, anticholinergics, or other medications likely to substantially affect autonomic or symptom outcomes.
  • Current participation in another interventional trial that could confound outcomes.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation technique that delivers mild electrical stimulation to the external ear at regions innervated by the auricular branch of the vagus nerve.

Placebo Comparator: Sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

tAVNS device with electrode placed at the external ear at regions with no active current.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Electroencephalography (EEG)
Time Frame: Baseline (Visit 2, pre-intervention) and Post Intervention (Visit 13, around 2 weeks from V2)

Resting Electroencephalography (EEG) will be recorded using a 64-channel system (resting alpha/theta power)

Baseline (Visit 2, pre-intervention) and Post Intervention (Visit 13, around 2 weeks from V2)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

June 30, 2028

Study Completion (Estimated)

June 30, 2029

Study Registration Dates

First Submitted

August 10, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2026P001468

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.